Business Performance - The company's operating revenue for 2024 was approximately ¥24.34 billion, a decrease of 9.67% compared to ¥26.95 billion in 2023[31]. - The net profit attributable to shareholders for 2024 was approximately ¥355.42 million, a significant increase of 123.29% from a loss of ¥1.53 billion in 2023[31]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥296.79 million, up 119.72% from a loss of ¥1.51 billion in 2023[31]. - The net cash flow from operating activities for 2024 was approximately ¥936.35 million, representing a 74.83% increase from ¥535.58 million in 2023[31]. - The basic earnings per share for 2024 was ¥0.248, a recovery from a loss of ¥1.0916 in 2023, marking a 122.72% improvement[31]. - The total assets at the end of 2024 were approximately ¥17.99 billion, an increase of 5.75% from ¥17.01 billion at the end of 2023[31]. - The net assets attributable to shareholders at the end of 2024 were approximately ¥5.89 billion, up 7.14% from ¥5.50 billion at the end of 2023[31]. - The company achieved operating revenue of CNY 24.343 billion, a year-on-year decrease of 9.67%[45]. - The net profit attributable to shareholders increased by 123.29% to CNY 355 million[45]. - The company reported a total of 4.3362 million pigs sold, representing a year-on-year growth of 16.80%[45]. Cost Management and Efficiency - The company has implemented a comprehensive disease prevention management system and cost management to enhance production efficiency and reduce costs[13]. - The company is enhancing its production processes by utilizing automated feeding and environmental control systems to improve operational efficiency[13]. - The company has adopted a centralized procurement strategy for raw materials to enhance bargaining power and control costs, ensuring a stable supply chain[10]. - The company reduced the cost of weaned piglets by 46.34 yuan per head compared to the previous year, with expectations for further cost reductions through ongoing investments in breeding and disease control[46]. - The company’s cost of pig fattening decreased by CNY 1.59 per kilogram year-on-year[45]. - The total operating costs decreased by 15.27% to 22,208,823.6 million, with feed costs accounting for 63.31% of total operating costs[73]. Market and Product Development - The company is investing in research and development of meat products to address food safety concerns and improve product quality[15]. - The company is expanding its market presence through strategic partnerships and investments in new technologies[6]. - The company is developing the "Xiangxiang Pig" premium fresh brand through technological innovations in nutrition formulation and breeding, promoting it via both online and offline channels[47]. - The company is focusing on optimizing its digital management system to enhance operational efficiency and decision-making capabilities[17]. - The company plans to expand its "company + farmer" model in regions like Hunan, Guangdong, and Guangxi to enhance profitability[45]. - The company is focusing on new product development, with an investment of 3.49 million in the latest quarter for research and development[109]. Financial Management and Fundraising - The company plans not to distribute cash dividends or issue bonus shares for the current period[18]. - The company has established a comprehensive management system that integrates various operational aspects to ensure steady development[61]. - The company has raised a total of RMB 299,999,997.00 from the issuance of 45,454,545 shares at a price of RMB 6.60 per share, with a net amount of RMB 292,991,294.69 after deducting issuance costs[103]. - The company has a remaining balance of 69,195.04 CNY in unused raised funds, which is stored according to relevant regulations[97]. - The company has redirected RMB 32 million from the "Chongqing Xiangda Biotechnology Co., Ltd. Animal Nutrition Biological Feed Research and Production Base Construction Project" to its subsidiary[114]. Governance and Compliance - The company has established a comprehensive governance structure and internal control system, adhering to relevant laws and regulations to enhance operational standards[145]. - The company is committed to maintaining independent operations, fully separating its business and financial activities from its controlling shareholder[146]. - The company has implemented various internal management systems, including major information reporting and investor relations management[145]. - The company held a total of 6 shareholder meetings in 2024, all conducted legally with the presence of a witnessing lawyer[146]. - The company emphasizes the independence of its operations from controlling shareholders in business, assets, personnel, and finance[150]. Research and Development - The company is focusing on digital transformation to reduce overall breeding costs and improve production and health metrics through AI and IoT technologies[60]. - The company has invested in advanced breeding systems and established partnerships with institutions like the Chinese Academy of Sciences to enhance its breeding capabilities[57]. - The company’s R&D personnel increased to 862 in 2024, a growth of 2.50% compared to 841 in 2023[80]. - R&D investment decreased by 23.34% to ¥101,524,602.56 in 2024 from ¥132,429,246.50 in 2023, representing 0.42% of operating revenue[80]. - The company is committed to enhancing its research and development capabilities in animal nutrition and feed production[119]. Employee Management and Training - The total number of employees at the end of the reporting period is 11,805, with 1,137 in the parent company and 10,668 in major subsidiaries[184]. - The training program in 2024 focused on digital transformation, talent development, and practical skills enhancement, with over 3,093 training sessions covering 120,000 participants and a skill qualification rate of 98%[188]. - The company has implemented a stock option incentive plan, with 403 participants eligible for 6,126,520 stock options in the second exercise period and 50 participants eligible for 822,100 stock options in the first reserved exercise period[193]. - The company emphasizes a "learning organization" ecosystem to support high-quality development through continuous training optimization[188]. - The company's compensation policy is based on annual business plans and performance contributions, aiming for external competitiveness and internal fairness[185].

Financial Performance - The company's revenue for Q1 2025 was CNY 5,973,387,459.78, representing a 22.40% increase compared to CNY 4,880,079,621.11 in the same period last year[4]. - The net loss attributable to shareholders decreased by 60.99% to CNY -77,051,603.93 from CNY -197,512,579.11 year-over-year[4]. - The net cash flow from operating activities improved significantly, reaching CNY 123,149,306.93, a 184.58% increase from CNY -145,605,740.39 in the previous year[4]. - Total operating revenue for the current period reached ¥5,973,387,459.78, an increase of 22.4% compared to ¥4,880,079,621.11 in the previous period[23]. - The net profit for the current period was a loss of ¥80,277,338.74, an improvement from a loss of ¥224,366,712.75 in the previous period[24]. - The total comprehensive income for the period was -80,277,338.74 CNY, compared to -224,366,712.75 CNY in the previous period, indicating an improvement[25]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 18,293,202,363.67, up 1.70% from CNY 17,987,160,209.45 at the end of the previous year[5]. - Current liabilities totaled ¥6,755,703,894.79, an increase from ¥6,257,475,895.75 in the prior period[21]. - Non-current liabilities decreased to ¥5,084,654,087.48 from ¥5,137,678,735.45 in the previous period[21]. - The company's total liabilities increased, with notes payable rising by 36.97% to CNY 740,702,044.00 due to increased procurement[9]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 80,593, with the largest shareholder holding 11.24% of the shares[12]. - The company repurchased 5,617,400 shares, accounting for 0.39% of the total share capital, with a total transaction amount of CNY 28,998,197, at a price range between CNY 4.87 and CNY 5.52 per share[15]. - The company has no significant changes in the shareholding structure of the top 10 shareholders due to margin trading activities[14]. Cash Flow - As of March 31, 2025, the company's cash and cash equivalents amounted to CNY 2,373,528,116.93, an increase from CNY 2,304,501,756.88 at the beginning of the period, reflecting a growth of approximately 2.9%[19]. - Cash inflow from operating activities was 6,376,263,024.95 CNY, up from 5,015,017,110.45 CNY in the previous period, representing a 27.1% increase[26]. - Cash inflow from investment activities was 675,633,594.88 CNY, compared to 351,441,175.68 CNY in the previous period, showing a 92.2% increase[27]. - The ending cash and cash equivalents balance was 2,087,037,485.40 CNY, down from 2,221,986,906.27 CNY in the previous period[27]. Operational Insights - The company reported a significant decrease in other income, down 41.10% to CNY 7,017,649.89, primarily due to reduced government subsidies[11]. - The company experienced a 68.82% reduction in asset disposal gains, reporting CNY -6,808,434.07 compared to CNY -21,834,638.72 in the previous year[11]. - The company's accounts receivable increased to CNY 333,888,202.28 from CNY 281,807,300.66, representing a growth of about 18.5%[19]. - The company's trading financial assets increased to CNY 22,255,080.61 from CNY 16,817,462.12, indicating a growth of about 32.5%[19]. - Research and development expenses were ¥31,638,376.28, a decrease from ¥44,890,002.39 in the previous period[24]. - The company reported an investment income of ¥5,724,708.16, significantly higher than ¥2,292,807.37 in the previous period[24]. Strategic Developments - The company has not disclosed any new product developments or market expansion strategies in the current report[14]. - The company is not currently engaged in any mergers or acquisitions as per the latest financial report[14]. - There are no significant changes in the company's operational strategies mentioned in the earnings call[14]. - The company's weighted average return on equity improved to -1.32% from -3.66% year-over-year[4]. - The company's basic and diluted earnings per share improved by 60.99%, both standing at CNY -0.0538 compared to CNY -0.1379 in the same period last year[4]. Audit Status - The company’s first quarter report was not audited[29].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002567 证券简称：唐人神 公告编号：2025-028 唐人神集团股份有限公司 关于子公司参与投资产业基金合伙企业的进展公告 统一社会信用代码：91440101MA5A3EJQ33 名称：广州大消费品壹期产业投资基金合伙企业（有限合伙） 类型：有限合伙企业 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 唐人神集团股份有限公司（以下简称"公司"）于2017年11月24日召开了第七届董事会第二十六次会议， 审议通过了《关于子公司参与投资产业基金合伙企业的议案》，同意全资子公司深圳前海唐人神投资有 限公司（以下简称"前海唐人神"）作为有限合伙人以自有资金50,000,000元投资广州大消费品壹期产业 投资基金合伙企业（有限合伙）（以下简称"大消费品基金"）。大消费品基金历次变更情况详见公司刊 登在巨潮资讯网（www.cninfo.com.cn）的《关于子公司参与投资产业基金合伙企业的进展公告》。 2025年3月10日，大消费品基金召开合伙人会议，决议：大消费品基金认缴出资额由200,000,000元减 ...

证券代码：002567 证券简称：唐人神 公告编号：2025-027 唐人神集团股份有限公司 关于第三期员工持股计划 第一个锁定期届满的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 唐人神集团股份有限公司（以下简称"公司"、"唐人神"）分别于 2024 年 3 月 6 日、2024 年 3 月 26 日召开第九届董事会第二十三次会议、2024 年第二 次临时股东大会，审议通过了《关于<第三期员工持股计划（草案）>及摘要的议 案》、《关于<第三期员工持股计划管理办法>的议案》、《关于提请股东大会授 权董事会办理公司第三期员工持股计划相关事宜的议案》。鉴于公司第三期员工 持股计划第一个锁定期于 2025 年 4 月 11 日届满，根据中国证券监督管理委员会 《关于上市公司实施员工持股计划试点的指导意见》及《深圳证券交易所上市公 司自律监管指引第 1 号-主板上市公司规范运作》相关规定，现将第三期员工持 股计划第一个锁定期届满后的相关情况公告如下： 一、本次员工持股计划持股情况和锁定期 （一）本次员工持股计划持股初始情况 本次员工持股计划的股票来源为公司回购 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002567 证券简称：唐人神 公告编号：2025-026 唐人神集团股份有限公司 2025年3月生猪销售简报 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、生猪销售情况 2025年3月公司生猪销量同比增长的主要原因是"公司+农户"养殖模式的生猪出栏量增加。 三、风险提示 （一）上述披露仅包含公司生猪养殖业务销售情况，不含饲料、肉品等业务情况。 （二）生猪市场价格波动的风险是整个生猪生产行业的系统风险，对任何一家生猪生产者来说，都是客 观存在的、不可控制的外部风险。生猪市场价格的大幅波动（下降或上升），都可能会对公司的经营业 绩产生较大影响。 四、其他提示 唐人神集团股份有限公司（以下简称"公司"）2025年3月生猪销量40.49万头（其中商品猪38.02万头，仔 猪2.47万头），2024年3月生猪销量34.68万头（其中商品猪28.9万头，仔猪5.78万头），同比上升 16.75%，环比上升1.63%；销售收入合计68,678万元，同比上升32.31%，环比上升0.90%。 2025年1-3 ...

证券代码：002567 证券简称：唐人神 公告编号：2025-026 唐人神集团股份有限公司 2025 年 3 月生猪销售简报 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、生猪销售情况 唐人神集团股份有限公司（以下简称"公司"）2025 年 3 月生猪销量 40.49 万头（其中商品猪 38.02 万头，仔猪 2.47 万头），2024 年 3 月生猪销量 34.68 万头（其中商品猪 28.9 万头，仔猪 5.78 万头），同比上升 16.75%，环比 上升 1.63%；销售收入合计 68,678 万元，同比上升 32.31%，环比上升 0.90%。 上述数据未经审计，与定期报告披露的数据之间可能存在差异，因此上述 数据仅作为阶段性数据供投资者参考。 二、原因说明 2025 年 3 月公司生猪销量同比增长的主要原因是"公司+农户"养殖模式 的生猪出栏量增加。 三、风险提示 （一）上述披露仅包含公司生猪养殖业务销售情况，不含饲料、肉品等业 务情况。 （二）生猪市场价格波动的风险是整个生猪生产行业的系统风险，对任何 一家生猪生产者来说，都是客观存在的、不 ...

唐人神集团股份有限公司 关于为子公司担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 唐人神集团股份有限公司（以下简称"公司"）分别于 2024 年 11 月 29 日、 2024 年 12 月 20 日召开第九届董事会第三十次会议、2024 年第五次临时股东大 会，审议通过了《关于 2025 年公司及子公司担保额度预计的议案》，根据公司 及子公司日常生产经营需要，公司及子公司（含授权期限内新设立或纳入的子 公司）向业务相关方（包括但不限于银行、金融机构、融资租赁公司、供应商 等）申请授信、借款、保理业务、融资租赁业务、采购或其他履约义务，公司 及子公司提供担保总额不超过 86.5 亿元，额度在有效期内可循环使用，即任一 时点的担保总额不超过 86.5 亿元，有效期为 2025 年 1 月 1 日至 2025 年 12 月 31 日。 上述担保包括公司为子公司提供担保、子公司为母公司提供担保、子公司 之间互相担保。担保范围包括但不限于申请银行借款、融资租赁等融资业务、 保理业务、采购履约担保等业务，担保方式包括但不限于连带责任担保、信用 担保、保 ...

证券代码：002567 证券简称：唐人神 公告编号：2025-024 唐人神集团股份有限公司 关于股份回购进展情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 唐人神集团股份有限公司（以下简称"公司"）于 2024 年 11 月 8 日召开 第九届董事会第二十八次会议，审议通过了《关于回购公司股份方案的议案》， 具体内容详见公司于 2024 年 11 月 9 日在巨潮资讯网披露的《关于回购公司股 份方案的公告暨回购报告书》等相关公告。 一、回购公司股份的进展情况 根据《深圳证券交易所上市公司自律监管指引第 9 号—回购股份》等有关 规定，公司应当在每个月的前三个交易日内披露截至上月末的回购进展情况。 现将公司回购进展情况公告如下： 截至 2025 年 3 月 31 日，公司通过股份回购专用证券账户以集中竞价方式回 购公司股份 5,617,400 股，占公司目前总股本的 0.39%，最高成交价为 5.52 元/股， 最低成交价为 4.87 元/股，成交金额 28,998,197 元（不含交易费用）。本次回购 价格未超过回购方案中拟定的 7.8 元/股。 ...

证券代码：002567 证券简称：唐人神 投资者关系活动记录表 | | ■ 特定对象调研 □ 分析师会议 | | --- | --- | | 投资者关系 | □ 媒体采访 □ 业绩说明会 | | 活动类别 | □ 新闻发布会 □ 路演活动 | | | □ 现场参观 □其他：电话会议 | | | 东方财富证券：王依依 图灵投资：周书冬 | | 参与单位名称 | 世纪量子资本：黄凯伟 知远投资：雷志华 | | 及人员姓名 | 蓝马资本：韩圣浩 顺从投资：邱曙 | | | 北斗星投资：张柘豪 个人投资者：杨桑 | | 时 间 | 年 月 日 2025 3 24 16:00-17:00 | | 地 点 | 公司总部会议室 | | 上市公司 | 董事会秘书：孙双胜 | | 接待人员姓名 | 证券部总经理：徐岩 | | | 证券部高级经理：谭勇波 | | | 第一：介绍阶段 | | | 介绍公司基本情况、发展战略（见已公开披露的信息）。 | | | 第二：问答阶段 | | | Q：公司生猪养殖产能及出栏量主要分布区域？ | | | A：公司生猪产业主要发展方向是布局猪肉消费区域。目前公司生猪出 | | | 栏量及产能大部 ...